Subscribe to NRx Newsletter

Prof Jonathan Javitt

NRx Pharmaceuticals Announces Leadership Transition

NRx Pharmaceuticals, a clinical-stage, biopharmaceutical company, today announced that Jonathan Javitt, MD, MPH, has retired as Chief Executive Officer effective immediately. The Board of Directors appointed Robert Besthof, Head of Operations and Chief Commercial Officer, as Interim CEO.